Search

everythinglearnresearchcommunity

for

Search:↓

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.

The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

Dr. Tsuji's stem cell hair multiplication procedure may offer a future solution for hair loss, but it is initially expected to be very expensive, with prices potentially decreasing over time. In the meantime, users discuss using treatments like finasteride, despite side effects, to manage hair loss.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

A user shared their experience with hair loss treatments, including I-PRF injections, mesotherapy, and a topical solution containing Minoxidil and Finasteride. After experiencing side effects, they decided to stop the medicinal treatments and focus on natural alternatives like I-PRF, microneedling, and essential oils.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

A user shared their experience with scalp micropigmentation (SMP) after one year. They discussed using Minoxidil, finasteride, and RU58841 as treatments for hair loss.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

The conversation discusses potential hair loss treatments, including hair cloning, setipiprant, and topical finasteride, questioning their availability and effectiveness as permanent cures. The user is inquiring about the release dates and efficacy of these treatments.